Facebook
Twitter
LinkedIn
ForwardInnovative and accredited continuing medical education
for today’s practicing clinicians.
CME Institute is trusted by physicians across medical specialties for premium continuing education that yields the highest educational outcomes. These ACCME-accredited activities make the latest research, novel therapies, and clinical best practices accessible and approachable for physician, NP, PA, and PharmD learners.
Expert-led insights to improve patient outcomes
Multi-modal courses to suit all learning styles
Timely topics for relevant application to practice
Razor-focused approach to innovation that includes documentary-style video and micro-learning Tweetorials
A commitment to collective mindfulness
Recent courses
Due to Wilson disease myriad manifestations, its rarity, and its range of symptoms, differential diagnosis may be challenging, leading to delays in treatment. This Neuroscience Commentary reviews diagnostic acumen and the latest updates in the field.
|
Clinicians should screen regularly for signs and symptoms of tardive dyskinesia and educate patients and caregivers on what to look for and report, leading to earlier intervention and better quality of life.
|
Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.
|
Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.
|
Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
|
Balancing symptoms and side effects is difficult when treating patients with schizophrenia. New approaches to treatment and new therapies in the pipeline offer hope for this difficult-to-treat mental health disorder.
|
Bipolar disorder presents on a spectrum, with bipolar depression on one end and bipolar I on the other and a host of other presentations in between. As guidelines are updated and new treatments become available, developing individualized treatment regimens is key and collaboration between clinician and patient and family is critical in optimizing patient outcomes. Clinicians should use measurement-based care to assess whether treatment changes are necessary, which requires engaging with the patient to monitor efficacy and manage side effects.
|
Symptoms and disease pathophysiology of myasthenia gravis (MG) vary considerably with each patient, and their individual preferences and priorities add to the need for individualized treatment of this autoimmune disease. Research in MG has grown substantially in recent years. New treatments have the potential of being both effective and well tolerated, addressing the trade-off of choosing either efficacy or tolerability when selecting treatments. Promising investigational treatments that may become available in the future may allow more patients than ever before to achieve an asymptomatic state, with the ultimate goal being to turn off abnormal antibody production.
|
Long COVID symptoms are both physical and mental in nature among children and adolescents and have the potential to affect long-term functioning and increase the overall burden on health care delivery.
|
Drs Goldberg, Swartz, and DelBello discuss the spectrum of bipolar disorder, from major depressive disorder to bipolar I, and assessment strategies for establishing accurate diagnoses, including age, gender, signs and symptoms, and comorbidities to facilitate appropriate treatments and improve patient outcomes.
|
As novel agents join the treatment landscape for bipolar I and bipolar II disorder and new data emerge on existing therapeutics, clinicians need education on the latest evidence of the safety and efficacy profiles of existing and emerging treatments for bipolar I and bipolar II disorder. Join Drs Goldberg, DelBello, and Swartz in examining how to integrate this information into clinical practice and provide efficacious and tolerable treatment for patients with bipolar I and bipolar II disorder.
|
Treating bipolar I and bipolar II depression is not one-size-fits-all. Learn from field experts about practice guidelines, novel agents, and approaches to developing personalized treatment plans for patients with bipolar depression type I and type II.
|
Pages
My Courses
Please login or create an account to view your activities.
Transcript
Please login or create an account to view your activities.